KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Exact Sciences (EXAS) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Exact Sciences (EXAS) over the last 15 years, with Q4 2024 value amounting to $2.6 million.

  • Exact Sciences' Other Operating Expenses fell 5987.5% to $2.6 million in Q4 2024 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year decrease of 8029.47%. This contributed to the annual value of $9.2 million for FY2024, which is 8826.93% down from last year.
  • Per Exact Sciences' latest filing, its Other Operating Expenses stood at $2.6 million for Q4 2024, which was down 5987.5% from $3.1 million recorded in Q3 2024.
  • Exact Sciences' 5-year Other Operating Expenses high stood at $393.5 million for Q2 2022, and its period low was -$13.2 million during Q3 2022.
  • Over the past 5 years, Exact Sciences' median Other Operating Expenses value was $98.1 million (recorded in 2020), while the average stood at $153.2 million.
  • In the last 5 years, Exact Sciences' Other Operating Expenses soared by 64384.63% in 2023 and then tumbled by 9569.61% in 2024.
  • Quarter analysis of 5 years shows Exact Sciences' Other Operating Expenses stood at $169.4 million in 2020, then surged by 96.32% to $332.6 million in 2021, then crashed by 103.98% to -$13.2 million in 2022, then surged by 148.32% to $6.4 million in 2023, then tumbled by 59.88% to $2.6 million in 2024.
  • Its Other Operating Expenses stands at $2.6 million for Q4 2024, versus $3.1 million for Q3 2024 and $3.8 million for Q2 2024.